1
|
Gao J, Chen Y, Wu P, Wang F, Tao H, Shen Q, Wang S, Gong S, Zhang X, Zhou Z, Song X, Jia Y. Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis. BMC Cancer 2021; 21:955. [PMID: 34433456 PMCID: PMC8390285 DOI: 10.1186/s12885-021-08683-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2021] [Accepted: 08/09/2021] [Indexed: 02/08/2023] Open
Abstract
Background The improved prognosis of classic Hodgkin lymphoma (cHL) has been accompanied by elevated risks of non–cancer-specific death (non-CSD). The aim of this study was to verify the occurrence of non-CSD and its effect on rates of overall survival among adult patients with cHL. Methods To ensure sufficient follow-up time, we analyzed retrospective data from patients aged ≥20 years with cHL that was diagnosed between 1983 and 2005 in the Surveillance, Epidemiology, and End Results (SEER) database. Logistic regression was applied to analyze the non-CSD occurrence in relation to all factors. Using Fine-Gray’s method, we calculated the cumulative incidences of CSD and non-CSD. Stacked cumulative incidence plots and ratio of non-CSD to all causes of death were applied to evaluate the effect of non-CSD on rates of overall survival. Finally, we analyzed long-term mortality through Cox proportional hazard regression analysis and competing risk regression analysis to emphasize a more appropriate model of survival for patients with cHL. Results Among the 18,518 patients included, there were 3768 cases of CSD (20.3%) and 3217 of non-CSD (17.4%). Older age, earlier period, male sex, unmarried status, mixed cellularity (MC) and lymphocyte-depletion (LD) histological subtype, and patients received radiotherapy (RT) only were associated with more non-CSD according to binary logistic analysis. The cumulative incidence of non-CSD exceeded CSD after approximately 280 months follow-up. The most common causes of non-CSDs were cardiovascular disease, subsequent primary neoplasms, infectious diseases, accidents, and suicide. In a Cox proportional hazards model, patients who were black, unmarried, at an advanced stage or underwent chemotherapy (CT) alone were at greater risk of mortality than were white patients, who were married, at an early stage, and underwent combined modality; these populations were also found to be at greater risk for CSD in a competing risk model, but the risk of non-CSD did not differ significantly according to race and marital status, patients with early-stage disease and who underwent RT only were found to be at higher risk of non-CSD instead. Conclusions Lymphoma was the cause of death in most patients who died, but non-CSD was not unusual. Patients with cHL should be monitored closely for signs of cardiovascular disease and malignant tumors. Rates of overall survival of patients were diminished by non-CSD, and a competing risk model was more suitable for establishing the prognosis than was the Cox proportional hazards model. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-08683-x.
Collapse
Affiliation(s)
- Jie Gao
- Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Yingying Chen
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
| | - Pengqiang Wu
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.,Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Fujue Wang
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.,Department of Hematology, The First Affiliated Hospital of University of South China, Hengyang, China
| | - Huan Tao
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
| | - Qianqing Shen
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
| | - Shuoting Wang
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
| | - Shuaige Gong
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
| | - Xue Zhang
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
| | - Zhencang Zhou
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.,Department of Hematology, The Third Affiliated Hospital of Zunyi Medical University, Guizhou, China
| | - Xianmin Song
- Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
| | - Yongqian Jia
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
| |
Collapse
|
2
|
Applying Data Science methods and tools to unveil healthcare use of lung cancer patients in a teaching hospital in Spain. Clin Transl Oncol 2019; 21:1472-1481. [PMID: 30864021 DOI: 10.1007/s12094-019-02074-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Accepted: 02/25/2019] [Indexed: 10/27/2022]
Abstract
PURPOSE Our primary goal was to study the use of outpatient attendances by lung cancer patients in Hospital Universitario Puerta de Hierro Majadahonda (HUPHM), Spain, by leveraging our Electronic Patient Record (EPR) and structured clinical registry of lung cancer cases as well as assessing current Data Science methods and tools. METHODS/PATIENTS We applied the Cross-Industry Standard Process for Data Mining (CRISP-DM) to integrate and analyze activity data extracted from the EPR (9.3 million records) and clinical data of lung cancer patients from a previous registry that was curated into a new, structured database based on REDCap. We have described and quantified factors with an influence in outpatient care use from univariate and multivariate points of view (through Poisson and negative binomial regression). RESULTS Three cycles of CRISP-DM were performed resulting in a curated database of 522 lung cancer patients with 133 variables which generated 43,197 outpatient visits and tests, 1538 ER visits and 753 inpatient admissions. Stage and ECOG-PS at diagnosis and Charlson Comorbidity Index were major contributors to healthcare use. We also found that the patients' pattern of healthcare use (even before diagnosis), the existence of a history of cancer in first-grade relatives, smoking habits, or even age at diagnosis, could play a relevant role. CONCLUSIONS Integrating activity data from EPR and clinical structured data from lung cancer patients and applying CRISP-DM has allowed us to describe healthcare use in connection with clinical variables that could be used to plan resources and improve quality of care.
Collapse
|
3
|
Muzumder S, Nirmala S, Avinash HU, Kainthaje PB, Sebastian MJ, Raj JM. Early Competing Deaths in Locally Advanced Head-and-Neck Cancer. Indian J Palliat Care 2018; 24:446-450. [PMID: 30410256 PMCID: PMC6199832 DOI: 10.4103/ijpc.ijpc_91_18] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Introduction: The competing (noncancer) deaths have increased with aggressive treatment approach and better disease control in locally advanced head-and-neck cancer. Aim: The aim of this study is to find incidence, cause and predictors of early competing mortality in locally advanced head-and-neck cancer patients undergoing combined modality therapy. Subjects and Methods: In this retrospective study, a total of 125 locally advanced head-and-neck patients treated from January 2013 to June 2017 were analyzed. The total number of deaths, cause, and the time of death from the start of therapy was recorded. To study the risk factors of competing deaths, univariate and multivariate logistic regression was applied. Data were analyzed using SPSS v. 24 software. Results: A total of 51 deaths (31 cancer deaths and 20 competing deaths) recorded at a median follow-up of 16 months (1–62 months). The incidence of early competing mortality was 12% (n = 15) with a median time of 2.7 months from treatment initiation. Sepsis was major cause of early competing death (n = 13). On univariate and multivariate logistic regression analysis, competing death was significantly associated with pharyngeal (oropharynx, hypopharynx, and larynx) site primary (odds ratio [OR] = 3.562; 95% confidential interval [CI] = 1.207–10.517; P = 0.016), and Stage IVA/IVB disease (OR = 5.104; 95% CI = 1.123–23.202; P = 0.021). Conclusion: Competing deaths is one of the multifaceted problems in locally advanced head-and-neck cancer patients. Sepsis being single most cause of early competing deaths in Stage IVA/IVB pharyngeal and laryngeal cancer.
Collapse
Affiliation(s)
- Sandeep Muzumder
- Department of Radiation Oncology, St. John's Medical College and Hospital, Bengaluru, Karnataka, India
| | - S Nirmala
- Department of Radiation Oncology, St. John's Medical College and Hospital, Bengaluru, Karnataka, India
| | - H U Avinash
- Department of Radiation Oncology, St. John's Medical College and Hospital, Bengaluru, Karnataka, India
| | - Prashanth Bhat Kainthaje
- Department of Radiation Oncology, St. John's Medical College and Hospital, Bengaluru, Karnataka, India
| | - Mg John Sebastian
- Department of Radiation Oncology, St. John's Medical College and Hospital, Bengaluru, Karnataka, India
| | - John Michael Raj
- Department of Biostatistics, St. John's Medical College, Bengaluru, Karnataka, India
| |
Collapse
|
4
|
Goyal G, Maldonado EB, Fan TJ, Kanmanthareddy A, Silberstein PT, Go RS, Armitage JO. Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2017; 17:812-818. [DOI: 10.1016/j.clml.2017.09.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Accepted: 09/11/2017] [Indexed: 01/03/2023]
|
7
|
Bessell EM, Bouliotis G, Armstrong S, Baddeley J, Haynes AP, O'Connor S, Nicholls-Elliott H, Bradley M. Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts. Br J Cancer 2012; 107:531-6. [PMID: 22713660 PMCID: PMC3405204 DOI: 10.1038/bjc.2012.228] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Background: The Nottinghamshire Lymphoma Registry contains the details of all the patients diagnosed with lymphoma (since 1 January 1973) within a defined geographical area with a population of 1.1 million. It was therefore possible to study the outcome of treatment for Hodgkin’s disease for three 10-year cohorts (1973–1982, 1983–1992 and 1993–2002). The aims of the study were to compare survival time among the three patient cohorts, to identify prognostic factors and to estimate relative survival. Methods: A total of 745 patients diagnosed between 1973 and 2002 were analysed for survival. Survivorship was estimated by the Kaplan-Meier method and parametric survival models. An accelerated failure-time regression was used for multivariate analysis. Results: Overall, patients were observed for 9.8 (0.3–34.82) years (median(range)), on average. One, five and fifteen-year disease-specific survival was found to be 87% (85–90%), 77% (74–80%) and 70% (67–74%), respectively. For those for diagnosed between 1973 and 1982, the 15-year survival was found to be 57% for 1983–1992, it was 74% and for 1993–2002, it was 83% (P<0.001). The difference remained significant after adjusting for prognostic factors. The actuarial risk of developing a second malignancy at 20 years was for the 1973–1982 cohort, 12.4%, and for the 1983–1992 cohort, 18.8%. Conclusion: Treatment advances and effective management of toxicities of treatment over time, have resulted in a significantly longer survival for patients with Hodgkin’s disease diagnosed within a defined population.
Collapse
Affiliation(s)
- E M Bessell
- Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol 2010; 2011:725219. [PMID: 21197477 PMCID: PMC3010617 DOI: 10.1155/2011/725219] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2010] [Accepted: 10/19/2010] [Indexed: 11/17/2022] Open
Abstract
Hodgkin lymphoma (HL) demonstrates heterogenous histologic findings, clinical presentation, and outcomes. Using the United States Surveillance, Epidemiology, and End Results (SEER) data we examined relationships between patient characteristics, clinical features at diagnosis, and survival in HL patients. From 2000 to 2007, 16,710 cases were recorded in 17 SEER registries. Blacks and Asians had low incidence (black/white incidence rate ratio (IRR) 0.86, P < .01; Asian/white IRR 0.43, P < .01). The bimodal pattern of incidence was less prominent for black males. Asians and Blacks presented at a mean age of 38 years compared to 42 years for Whites (P < .001). Race was a predictor for survival with HR of 1.19 (95% CI 1.11-1.28) for Blacks. Age was the most important predictor of survival (HR for patients ≥45 years 5.08, 95% CI 4.86-5.31). These current patterns for presentation and outcomes of HL help to delineate key populations in order to explore risk factors for HL and strategies to improve treatment outcomes.
Collapse
|
10
|
Kiserud CE, Loge JH, Fosså A, Holte H, Cvancarova M, Fosså SD. Mortality is persistently increased in Hodgkin's lymphoma survivors. Eur J Cancer 2010; 46:1632-9. [PMID: 20219350 DOI: 10.1016/j.ejca.2010.02.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2009] [Revised: 02/04/2010] [Accepted: 02/08/2010] [Indexed: 11/30/2022]
Abstract
BACKGROUND Negative health outcomes of chronic fatigue (CF) in disease-free cancer survivors are mainly unexplored. Aims of this study were to examine mortality and causes of death in Hodgkin's lymphoma survivors (HLSs) compared to controls from the general population, and to explore if CF was associated with increased mortality. METHODS HLSs (n=557) invited to participate in a survey on late effects in 1994 were divided into three groups: participants without CF (n=329), participants with CF (n=113), non-participants (n=98). Controls matched for gender and age were drawn from the general population (five per HLSs, n=2785). Observation time was calculated from 1st January 1994 until date of death or cut-off at 1st January 2007. Kaplan-Meier plots were used for univariate analyses and Cox models for multiple covariates. RESULTS Compared to controls HLSs had nearly five times higher mortality (HR=4.93; 95% confidence interval [CI]: 3.91-6.21) and the mortality rate of HLSs was higher than the rate of their controls for the entire observation period. Mortality was increased in all groups: participants with CF: HR=4.85 (95% CI: 3.02-7.77), participants without CF: HR=4.35 (95% CI: 3.16-6.00), non-participants: HR=9.45 (95% CI: 5.44-16.41). Compared to the controls HLSs had over six times increased mortality of cancer (HR: 6.6, 95% CI: 4.7-9.2) and almost five times increased mortality of cardiovascular diseases (HR: 4.9, 95% CI: 3.1-7.9). CONCLUSIONS HLSs had almost five-time increased mortality compared to controls. CF was not associated with increased mortality rate. The high mortality among the non-participating HLSs indicates that serious health problems are underestimated in this group. This has implications for the interpretation of surveys in cancer survivors.
Collapse
Affiliation(s)
- Cecilie E Kiserud
- National Resource Center for Late Effects, Department of Oncology, Oslo University Hospital and University of Oslo, Norway.
| | | | | | | | | | | |
Collapse
|